Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
Barbui, Tiziano , Thiele, Jürgen, Carobbio, Alessandra , Guglielmelli, Paola , Rambaldi, Alessandro , Tefferi, Ayalew , Vannucchi, Alessandro M. , Rambaldi, Alessandro , Guglielmelli, Paola

American Journal of Hematology | February 18, 2014 | Volume: 89 | Issue: 6 | Pages: 588-590

10.1002/ajh.23694 | PMID 24535932 Get It

In patients not meeting the required hematocrit (HCT) or hemoglobin (Hb) thresholds according to BCSH and the WHO diagnostic criteria, the diagnosis of masked polycythemia vera (mPV) has been proposed. A comparison of HCT or Hb values with the expression of JAK2V617F, JAK2 exon 12, and CALR mutations in strictly WHO‐defined 257 overt PV and 140 mPV (59 mPV according to BCSH) and 397 patients with essential thrombocythemia (ET) was performed. Hb and HCT thresholds of mPV patients were significantly higher than JAK2V617F ET (P < 0.0001). The best cut‐off for Hb to discriminate JAK2‐mutated ET from PV was 16.5 g/dL for males and 16.0 g/dL for females. For HCT, this was 49% in males and 48% in females. The proportion of patients correctly classified as ET or PV when regarding Hb or HCT levels was 95% in males and 93% in females and 94% in both males and females, respectively. Am. J. Hematol. 89:588–590, 2014. © 2014 Wiley Periodicals, Inc.
An Historical Perspective on Ulnar Intraneural Ganglion Cysts and Their Joint Origins
Spinner, Robert J. , Harish, Srinivasan, Amrami, Kimberly K.

HAND | February 18, 2014 | Volume: 9 | Issue: 3 | Pages: 395-398

10.1007/s11552-014-9608-z | PMID 25191175 Get It

Key sleep neurologic disorders
Louis, Erik K. St. , St Louis, Erik K

Neurology Clinical Practice | February 17, 2014 | Volume: 4 | Issue: 1 | Pages: 16-25

10.1212/01.cpj.0000442523.60659.02 | PMID 24605270 Get It

Health literacy and medication awareness in outpatient neurology
Fleisher, Jori , Margus, Colton , Pruitt, Amy A. , Bhatia, Roma, Pruitt, Amy, Dahodwala, Nabila, Bhatia, Roma , Dahodwala, Nabila A.

Neurology Clinical Practice | February 17, 2014 | Volume: 4 | Issue: 1 | Pages: 71-81

10.1212/01.cpj.0000436211.73013.ab | PMID 24605271 Get It

Tenosynovitis of the Wrist and Thumb and Carpal Tunnel Syndrome Caused by Histoplasma Capsulatum : Case Report and Review of the Literature
Vitale, Mark A. , Roden, Anja C. , Rizzo, Marco

HAND | February 17, 2014 | Volume: 10 | Issue: 1 | Pages: 54-59

10.1007/s11552-014-9611-4 | PMID 25762883 Get It

A patient presenting with acute carpal tunnel syndrome and swelling and pain in the wrist and thumb is presented. An open carpal tunnel release and tenosynovectomy were performed with biopsy specimen revealing infection with Histoplasma capsulatum. The case is discussed in context of the prior scant literature of tenosynovitis of the wrist and hand caused by histoplasmosis.
Infusion technique of hematopoietic progenitor cells and related adverse events (CME)
Mulay, Sudhanshu , Greiner, Carl, Mohr, Amy, Bryant, Sandra C. , Lingineni, Ravi K., Padley, Doug, Gastineau, Dennis A., Jacob, Eapen K., Hogan, William J. , Gastineau, Dennis A.

Transfusion | February 17, 2014 | Volume: 54 | Issue: 8 | Pages: 1997-2003

10.1111/trf.12572 | PMID 24697759 Get It

BackgroundThe use of hematopoietic progenitor cell (HPC) transplant has risen over the past two decades. A variety of adverse events (AEs) of varying severity have been noted during HPC infusions. These AEs have been associated with several factors such as the amount of dimethyl sulfoxide and white blood cells in the HPC product. We performed a single‐institution retrospective analysis to determine the effect of two different HPC infusion techniques, manual push with syringes versus infusion from bags with the aid of gravity, on the occurrence of infusion‐related AEs.Study Design and MethodsInfusions between December 2008 and November 2010 involving peripheral blood HPCs were reviewed. Pertinent clinical and HPC product–related information was recorded. Data were analyzed to determine the incidence of infusion‐related AEs and its association with patient and product‐related variables.ResultsWe found 461 AEs in 645 patients during the study period. A total of 325 (50%) experienced at least one AE. Flushing was the most common type of AE followed by nausea and hypertension. The use of syringe infusion was more commonly associated with AEs (odds ratio, 1.82 [95% confidence interval, 1.32‐2.50]; p = 0.002). Other independent risk factors were cryopreserved products and the amount of polymorphonuclear leukocytes in the product.ConclusionTo our knowledge, this is the first study examining the effect of two different infusion techniques on infusion‐related AEs. Our findings suggest that the use of bags for infusion protected the patients from AEs.
Clinical spectrum of neuromyelitis optica 2013
Weinshenker, Brian G. , Weinshenker, Brian G

Neurology and Clinical Neuroscience | February 17, 2014 | Volume: 2 | Issue: 2 | Pages: 23-27

10.1111/ncn3.79 Get It

AbstractThe spectrum of presentation of neuromyelitis optica (NMO) is now recognized as being more diverse than defined by current diagnostic criteria, and includes limited forms of optic neuritis and transverse myelitis, as well as other brain syndromes. Discovery of a specific biomarker, autoantibodies targeting aquaporin‐4, facilitated the recognition of this broader spectrum of disease. Brain magnetic resonance imaging lesions in NMO might be relatively specific or entirely non‐specific. The most specific lesions are lesions of the area postrema or hypothalamus, longitudinally extensive corpus callosum lesions, and long corticospinal tract lesions in the corona radiata and brainstem. Although the full spectrum of aquaporin‐4‐associated disease based on population‐based serological studies remains undefined, studies from service testing laboratories show that the vast majority of patients have had optic neuritis and myelitis or one of the now well‐accepted signature syndromes of NMO, such as intractable vomiting or hiccough, although ascertainment bias undoubtedly influences this conclusion. New diagnostic criteria based on deliberations of an international panel of experts are anticipated shortly. Almost certainly, new criteria will allow for diagnosis of NMO based on a single episode of a “signature” syndrome of NMO. Nevertheless, in the face of a syndrome that is less characteristic and less well associated with NMO, especially if associated with other disease entities, caution is necessary.
Reversible non‐ischaemic cardiomyopathy and left ventricular dysfunction after liver transplantation: a single‐centre experience
Yataco, Maria, Difato, Thomas, Bargehr, Johannes , Rosser, Barry G., Patel, Tushar , Trejo-Gutiérrez, Jorge F. , Pungpapong, Surakit , Aranda‐Michel, Jaime, Yataco, Maria L, Taner, C. Burcin , Patel, Tushar , Pungpapong, Surakit

Liver International | February 17, 2014 | Volume: 34 | Issue: 6 | Pages: No page available

10.1111/liv.12501 | PMID 24529030 Get It

AbstractBackground & AimsNon‐ischaemic cardiomyopathy (NIC) is an early complication of liver transplantation (LT). Our aims were to define the prevalence, associated clinical factors, and prognosis of this condition.MethodsA retrospective study was performed on patients undergoingLTat our institution from January 2005 to December 2012. Patients who developedNICwere identified. Data collected included demographic and clinical data.ResultsA total 1460 transplants were performed in this period and seventeen patients developedNIC. Pretransplant medianQTc interval was 459 (range, 405–530), and median E/A ratio was 1 (range, 0.71–1.67). Fourteen patients (82%) were severely malnourished and required nutritional support. Thirteen patients (76%) had renal insufficiency. Median time to onset was 2 days post‐transplant (range, 0–20). Echocardiograms showed global left ventricular hypokinesis and a decrease in ejection fraction (EF) from a median of 65% (range, 50–81) pretransplant to a median of 21% (range, 15–32). Median raw model for end‐stage liver disease (MELD) score was 29 in patients withNICvs. 18 in patients without cardiomyopathy (P = 0.01). There was no significant difference between recipients withNICvs. recipients without cardiomyopathy regarding donor age, donor risk index, and cold and warm ischaemia time. Recovery of cardiac function occurred in 16 patients, with a medianEFof 44% (range, 25–65%) at the time of discharge. The last echocardiogram available showed a medianEFof 59% (range, 49–73%). One‐year survival of NIC patients was 94.1%.ConclusionNon‐ischaemic cardiomyopathy is a rare complication afterLT. Patients withNICare critically ill, with highMELDscore, and severe malnutrition.
Performance of an Automatic Arrhythmia Classification Algorithm: Comparison to the ALTITUDE Electrophysiologist Panel Adjudications
Mahajan, Deepa, Dong, Yanting , Saxon, Leslie A. , Cha, Yong‐Mei , Gilliam, F. Roosevelt, Asirvatham, Samuel J. , Cesario, David A., Jones, Paul W. , Seth, Milan, Powell, Brian D. , Asirvatham, Samuel J

Pacing and Clinical Electrophysiology | February 17, 2014 | Volume: 37 | Issue: 7 | Pages: 889-899

10.1111/pace.12367 | PMID 24527748 Get It

IntroductionAdjudication of thousands of implantable cardioverter defibrillator (ICD)‐treated arrhythmia episodes is labor intensive and, as a result, is most often left undone. The objective of this study was to evaluate an automatic classification algorithm for adjudication of ICD‐treated arrhythmia episodes.MethodsThe algorithm uses a machine learning algorithm and was developed using 776 arrhythmia episodes. The algorithm was validated on 131 dual‐chamber ICD shock episodes from 127 patients adjudicated by seven electrophysiologists (EPs). Episodes were classified by panel consensus as ventricular tachycardia/ventricular fibrillation (VT/VF) or non‐VT/VF, with the resulting classifications used as the reference. Subsequently, each episode electrogram (EGM) data was randomly assigned to three EPs without the atrial lead information, and to three EPs with the atrial lead information. Those episodes were also classified by the automatic algorithm with and without atrial information. Agreement with the reference was compared between the three EPs consensus group and the algorithm.ResultsThe overall agreement with the reference was similar between three‐EP consensus and the algorithm for both with atrial EGM (94% vs 95%, P = 0.87) and without atrial EGM (90% vs 91%, P = 0.91). The odds of accurate adjudication, after adjusting for covariates, did not significantly differ between the algorithm and EP consensus (odds ratio 1.02, 95% confidence interval: 0.97–1.06).ConclusionsThis algorithm performs at a level comparable to an EP panel in the adjudication of arrhythmia episodes treated by both dual‐ and single‐chamber ICDs. This type of algorithm has the potential for automated analysis of clinical ICD episodes, and adjudication of EGMs for research studies and quality analyses.
Citalopram and escitalopram plasma drug and metabolite concentrations: genome‐wide associations
Schaid, Daniel J. , Desta, Zeruesenay , Kubo, Michiaki , Batzler, Anthony , Snyder, Karen, Ogburn, Evan T., Hall‐Flavin, Daniel K., Flockhart, David A., Nakamura, Yusuke , Mrazek, David A. , Weinshilboum, Richard M. , Ji, Yuan , Mushiroda, Taisei , Kamatani, Naoyuki , Weinshilboum, Richard M.

British Journal of Clinical Pharmacology | February 17, 2014 | Volume: 78 | Issue: 2 | Pages: 373-383

10.1111/bcp.12348 | PMID 24528284 Get It

Aims Citalopram ( CT ) and escitalopram ( S ‐ CT ) are among the most widely prescribed selective serotonin reuptake inhibitors used to treat major depressive disorder ( MDD ). We applied a genome‐wide association study to identify genetic factors that contribute to variation in plasma concentrations of CT or S ‐ CT and their metabolites in MDD patients treated with CT or S ‐ CT . Methods Our genome‐wide association study was performed using samples from 435 MDD patients. Linear mixed models were used to account for within‐subject correlations of longitudinal measures of plasma drug/metabolite concentrations (4 and 8 weeks after the initiation of drug therapy), and single‐nucleotide polymorphisms ( SNPs ) were modelled as additive allelic effects. Results Genome‐wide significant associations were observed for S ‐ CT concentration with SNPs in or near the CYP2C19 gene on chromosome 10 (rs1074145, P = 4.1 × 10 −9 ) and with S ‐didesmethylcitalopram concentration for SNPs near the CYP2D6 locus on chromosome 22 (rs1065852, P = 2.0 × 10 −16 ), supporting the important role of these cytochrome P450 ( CYP ) enzymes in biotransformation of citalopram. After adjustment for the effect of CYP2C19 functional alleles, the analyses also identified novel loci that will require future replication and functional validation. Conclusions In vitro and in vivo studies have suggested that the biotransformation of CT to monodesmethylcitalopram and didesmethylcitalopram is mediated by CYP isozymes. The results of our genome‐wide association study performed in MDD patients treated with CT or S ‐ CT have confirmed those observations but also identified novel genomic loci that might play a role in variation in plasma levels of CT or its metabolites during the treatment of MDD patients with these selective serotonin reuptake inhibitors.